Tacrolimus Adjustment by NFAT-related Gene Expression in Lung Allograft Recipients. — TANGELA

Transplantation, Lung Clinical Trial

Official title:
Tacrolimus Adjustment by NFAT-related Gene Expression in Lung Allograft Recipients.

Status Completed

Clinical Trial Summary

This is a non-interventional cohort study to assess a novel assay to detect excessive or insufficient immunosuppression from the drug tacrolimus in lung transplant recipients. The assay measures mean residual expression (MRE) of genes downstream of nuclear factor of activated T cells (NFAT), a transcription factor regulated by tacrolimus. The investigators will assess whether MRE levels identify subjects at risk for rejection (insufficient immunosuppression) or infection (excessive immunosuppression).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Transplantation, Lung

Clinical Trial Details

NCT number	NCT02278952
Study type	Observational
Source	University of California, San Francisco
Contact
Status	Completed
Phase
Start date	December 2014
Completion date	January 2018

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT04643665` - Prediction of Pulmonary Graft Dysfunction After Double-lung Transplantation (PGD3-AI Study)
	Recruiting	`NCT05125406` - Prevention of ICU-Related Anxiety in Lung Transplantation by Virtual Reality Therapy - PIRAT Study	N/A